# A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

> **NCT01224106** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 799 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Gantenerumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01224106
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-30
- **Primary completion:** 2020-09-10
- **Final completion:** 2020-09-10
- **Target enrollment:** 799 (ACTUAL)
- **Last updated:** 2021-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01224106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01224106, "A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01224106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*